Recombinant human vascular endothelial growth factor receptor-immunoglobulin Fc fusion protein(Huabo Biopharm)

重组人血管内皮生长因子受体-抗体融合蛋白（华博生物）

Report date: 2022/04/11 11:15:53

Base Information

Drug NameRecombinant human vascular endothelial growth factor receptor-immunoglobulin Fc fusion protein(Huabo Biopharm)

Drug Alias Name重组人血管内皮生长因子受体-抗体融合蛋白眼用注射液HB-002.1MHB002 MHB-002-1MHB-002.1

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionVascular endothelial growth factor inhibitors

TargetsVascular endothelial growth factor

Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

China Registration ClassClass 1 therapeutic biologic in China

Inactive CompaniesN/A

Active IndicationsDiabetic macular oedemaWet age-related macular degeneration

Inactive IndicationsMacular Degeneration

ATC CodeN/A